Copyright

*©2016 Cotiviti Corporation, all rights reserved. All confidential, proprietary information, names and logos contained herein shall at all times be and remain the sole and exclusive property of Cotiviti Corporation and its wholly owned subsidiaries.*

*CPT only copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.*

# factor IX, complex #

Brand name: PROFILNINE (FACTOR IX COMPLEX) KIT or BEBULIN (COAGULATION FACTOR IX HUMAN) KIT

J7194 (Factor ix, complex, per i.u.)

Version: 4

Release Date: unreleased

  


<table> 
 <thead> 
  <tr> 
   <th>Item</th> 
   <th>Item Details</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>[HCPCS] (Descriptor)</td> 
   <td>
    <div>
     J7194
    </div>
    <div>
     (Factor ix, complex, per i.u.)
    </div></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Route of administration</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Time of administration</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Administration codes</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>How supplied</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### References ###

<table> 
 <thead> 
  <tr> 
   <th>Reference type</th> 
   <th>Reference details</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>Drug Label</td> 
   <td>Drug Label, BEBULIN (factor IX, complex), October 2016<br />Drug Label, Profilnine (factor IX, complex), July 2015<br />Drug Label, Bebulin (factor IX, complex), July 2015<br />Drug Label, Profilnine (factor IX, complex), July 2015<br />Drug Label, Profilnine (factor IX, complex), July 2015<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Clinical Pharmacology</td> 
   <td>Clinical Pharmacology, factor IX, complex, April 2015<br />Clinical Pharmacology, factor IX, complex, April 2015<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Micromedex DrugDex</td> 
   <td>Micromedex DrugDex, factor IX, complex, November 2016<br />Micromedex DrugDex, factor IX, complex, July 2016<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Lexi-Drugs</td> 
   <td>Lexi-Drugs, factor IX, complex, December 2016<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>AHFS-DI</td> 
   <td>AHFS-DI, factor IX, complex, January 2017<br /></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### LCDs ###

<table> 
 <thead> 
  <tr> 
   <th>LCD</th> 
   <th>MAC name</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>A/BMAC/J-N/L33684/R-01-01-2017</td> 
   <td> First Coast Service Options, Inc. </td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>A/BMAC/J-H,J-L/L35111/R-10-01-2016</td> 
   <td> Novitas Solutions, Inc. </td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Medical journal ###

<table> 
 <thead> 
  <tr> 
   <th>Citation</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>&nbsp;</td> 
   <td>&nbsp;</td> 
  </tr> 
 </tbody> 
</table>

### Notes ###

<table> 
 <thead> 
 </thead> 
 <tbody> 
  <tr> 
   <td>&nbsp;</td> 
  </tr> 
  <tr> 
   <td>&nbsp;</td> 
  </tr> 
 </tbody> 
</table>

### Indications ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>&nbsp;Drug Label&nbsp;</th> 
   <th>&nbsp;Clinical Pharmacology&nbsp;</th> 
   <th>&nbsp;Micromedex DrugDex&nbsp;</th> 
   <th>&nbsp;NCCN&nbsp;</th> 
   <th>&nbsp;Lexi-Drugs&nbsp;</th> 
   <th>&nbsp;AHFS-DI&nbsp;</th> 
   <th>&nbsp;Other&nbsp;</th> 
   <th>&nbsp;CMS Policy&nbsp;</th> 
   <th>&nbsp;LCD&nbsp;</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>deficiency of coagulation factor due to liver disease</td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>hemophilia B</td> 
   <td align="center"> x </td> 
   <td align="center"> x </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>coumarin toxicity</td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>factor X deficiency</td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis codes ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>NCCN ICD-10</th> 
   <th>LCD ICD-10</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>deficiency of coagulation factor due to liver disease</td> 
   <td></td> 
   <td>D68.4</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>hemophilia B</td> 
   <td></td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>coumarin toxicity</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>factor X deficiency</td> 
   <td></td> 
   <td>D68.2</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis code Summary ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>ICD-10 codes</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>deficiency of coagulation factor due to liver disease</td> 
   <td>D68.4</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>hemophilia B</td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>coumarin toxicity</td> 
   <td>T45.511, T45.511A, T45.511D, T45.511S, T45.512, T45.512A, T45.512D, T45.512S, T45.513, T45.513A, T45.513D, T45.513S, T45.514, T45.514A, T45.514D, T45.514S, T45.515, T45.515A, T45.515D, T45.515S</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>factor X deficiency</td> 
   <td>D68.2</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis code Overlaps ###

<table> 
 <thead> 
  <tr> 
   <th>ICD-10 Code</th> 
   <th>Indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Manifestation Codes ###

<table> 
 <thead> 
  <tr> 
   <th>ICD-10 Code(s)</th> 
   <th>Indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Dosing Patterns ###

### Daily Maximum Dose ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Maximum dose</th> 
   <th>Maximum Units</th> 
  </tr> 
 </thead> 
 <tbody> 
 </tbody> 
</table>

### Maximum Frequency ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Days</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Age ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Age</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Gender ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Gender</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Visits over time ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Visits</th> 
   <th>Interval</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Units over time ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Units</th> 
   <th>Interval</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Combination therapy ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Combination</th> 
   <th>HCPCS</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Global Review ###

<table> 
 <thead> 
  <tr> 
   <th>Current indication</th> 
   <th>Global review indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td></td> 
   <td>coumarin toxicity</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>deficiency of coagulation factor due to liver disease</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>factor X deficiency</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>hemophilia B</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

  


<table> 
 <thead> 
  <tr> 
   <th>Current ICD-10 codes</th> 
   <th>Global review ICD-10 codes</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td></td> 
   <td>D68.4</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>T45.511, T45.511A, T45.511D, T45.511S, T45.512, T45.512A, T45.512D, T45.512S, T45.513, T45.513A, T45.513D, T45.513S, T45.514, T45.514A, T45.514D, T45.514S, T45.515, T45.515A, T45.515D, T45.515S</td> 
   <td></td> 
  </tr> 
  <tr> 
   <td></td> 
   <td>D68.2</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### factor IX, complex rules ###

<table> 
 <thead> 
  <tr> 
   <th>Mid Rule</th> 
   <th>Description</th> 
   <th>Comments</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed and a diagnosis of coumarin toxicity, deficiency of coagulation factor due to liver disease, factor X deficiency, or hemophilia B is not present on the claim header, then deny J7194 with reason The Diagnosis Codes On The Claim Do Not Support The Billed Procedure Code. Diagnosis codes: ICD-10 codes: D67, D68.2, D68.4, T45.511, T45.511A, T45.511D, T45.511S, T45.512, T45.512A, T45.512D, T45.512S, T45.513, T45.513A, T45.513D, T45.513S, T45.514, T45.514A, T45.514D, T45.514S, T45.515, T45.515A, T45.515D, T45.515S <h3>Script</h3> The billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), was denied because it was not reported with an approved diagnosis code, per our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia. <h3>Rationale</h3> According to our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia, factor IX, complex is appropriate for certain FDA-approved and non-FDA-approved indications. Label indication: hemophilia B; Non-label indications: coumarin toxicity, deficiency of coagulation factor due to liver disease, factor X deficiency <h3>Reference</h3> Drug Label, BEBULIN (factor IX, complex), October 2016; Drug Label, Profilnine (factor IX, complex), July 2015; Drug Label, Profilnine (factor IX, complex), July 2015; Clinical Pharmacology, factor IX, complex, April 2015; Clinical Pharmacology, factor IX, complex, April 2015; Micromedex DrugDex, factor IX, complex, November 2016; Micromedex DrugDex, factor IX, complex, July 2016; Lexi-Drugs, factor IX, complex, December 2016; AHFS-DI, factor IX, complex, January 2017; LCD: A/BMAC/J-N/L33684/R-01-01-2017; A/BMAC/J-H,J-L/L35111/R-10-01-2016 </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with units greater than 4,000 by any provider and any claim type and a diagnosis of coumarin toxicity is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (4,000 units of J7194) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis codes: ICD-10 codes: T45.511, T45.511A, T45.511D, T45.511S, T45.512, T45.512A, T45.512D, T45.512S, T45.513, T45.513A, T45.513D, T45.513S, T45.514, T45.514A, T45.514D, T45.514S, T45.515, T45.515A, T45.515D, T45.515S <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the pharmaceutical compendium. <h3>Rationale</h3> According to our policy, which is based on the pharmaceutical compendium, the maximum recommended daily dosage for factor IX, complex for the reported indication is 4,000 iu. Therefore, the additional units have been denied. <h3>Reference</h3> Micromedex DrugDex, factor IX, complex, November 2016 <h3>SubRule Note</h3> Dosing according to... </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with units greater than 17,040 by any provider and any claim type and a diagnosis of coumarin toxicity is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (17,040 units of J7194) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis codes: ICD-10 codes: T45.511, T45.511A, T45.511D, T45.511S, T45.512, T45.512A, T45.512D, T45.512S, T45.513, T45.513A, T45.513D, T45.513S, T45.514, T45.514A, T45.514D, T45.514S, T45.515, T45.515A, T45.515D, T45.515S <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the pharmaceutical compendium. <h3>Rationale</h3> According to our policy, which is based on the pharmaceutical compendium, the maximum recommended daily dosage for factor IX, complex for the reported indication is 150 iu/kg (17,040 iu or 17,040 units of J7194 for a 250 lb/113.6 kg/2.45 m2 patient). Therefore, the additional units have been denied. <h3>Reference</h3> Lexi-Drugs, factor IX, complex, December 2016 <h3>SubRule Note</h3> Dosing according to... </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with units greater than 3,408 by any provider and any claim type and a diagnosis of factor X deficiency is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (3,408 units of J7194) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis code: ICD-10 code: D68.2 <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the pharmaceutical compendium. <h3>Rationale</h3> According to our policy, which is based on the pharmaceutical compendium, the maximum recommended daily dosage for factor IX, complex for the reported indication is 30 iu/kg (3,408 iu or 3,408 units of J7194 for a 250 lb/113.6 kg/2.45 m2 patient). Therefore, the additional units have been denied. <h3>Reference</h3> Micromedex DrugDex, factor IX, complex, November 2016 <h3>SubRule Note</h3> Dosing according to... </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with units greater than 17,040 by any provider and any claim type and a diagnosis of hemophilia B is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (17,040 units of J7194) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis code: ICD-10 code: D67 <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia. <h3>Rationale</h3> According to our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia, the maximum recommended daily dosage for factor IX, complex for the reported indication is 150 iu/kg (17,040 iu or 17,040 units of J7194 for a 250 lb/113.6 kg/2.45 m2 patient). Therefore, the additional units have been denied. <h3>Reference</h3> Drug Label, BEBULIN (factor IX, complex), October 2016; Clinical Pharmacology, factor IX, complex, April 2015; Micromedex DrugDex, factor IX, complex, November 2016; Lexi-Drugs, factor IX, complex, December 2016; AHFS-DI, factor IX, complex, January 2017 <h3>SubRule Note</h3> Dosing according to... </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with units greater than 2,000 by any provider and any claim type and a diagnosis of deficiency of coagulation factor due to liver disease is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (2,000 units of J7194) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis code: ICD-10 code: D68.4 <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the pharmaceutical compendium. <h3>Rationale</h3> According to our policy, which is based on the pharmaceutical compendium, the maximum recommended daily dosage for factor IX, complex for the reported indication is 2,000 iu. Therefore, the additional units have been denied. <h3>Reference</h3> Micromedex DrugDex, factor IX, complex, November 2016 <h3>SubRule Note</h3> Dosing according to... </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7194&gt; is billed with modifier JW (Drug amount discarded/not administered to any patient) and the units equal or exceed 200, then deny J7194-JW with reason Procedure Inappropriately Coded. <h3>Script</h3> The billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), was denied because it was submitted with modifier JW (Drug amount discarded/not administered to any patient) and the units equaled or exceeded 200, per our policy, which is based on the FDA-approved package insert/prescribing information. <h3>Rationale</h3> According to our policy, which is based on the FDA-approved package insert/prescribing information, factor IX, complex is supplied in 200, 500, 1000, and 1500 iu single-use vials. It is expected that a provider will use a combination of vial sizes that eliminates or minimizes drug wastage. <h3>Reference</h3> Drug Label, Profilnine (factor IX, complex), July 2015; Drug Label, Bebulin (factor IX, complex), July 2015 </td>
   <td></td>
  </tr> 
 </tbody> 
</table>

  
dosage rule per indication enabled: true

  
generated on: Apr 8, 2017 1:14:45 AM  
